Xalkori (Crizotinib)

Buy Pfizer Xalkori (also called Crizalk in Europe) at an 77% discount from insulinhub.

According to the European Medicines Agency, brand name Xalkori originating from Europe is manufactured at the following site(s): Pfizer Manufacturing Deutschland GmbH Betriebsstӓtte Freiburg Mooswaldallee 1 79090 Freiburg Germany

Information about Xalkori (Crizotinib)

Xalkori contains crizotinib, a tyrosine kinase inhibitor that works by blocking the action of abnormal proteins caused by ALK or ROS1 gene mutations. These mutations are associated with the growth of certain cancers. By inhibiting these proteins, Xalkori can slow or stop the growth of cancer cells.

Product Highlights

• Xalkori is indicated for the treatment of adults with metastatic or advanced NSCLC that is positive for ALK or ROS1 gene rearrangement.
• Xalkori is also used for patients with other cancers that exhibit ALK gene rearrangement, although its primary use is in lung cancer.

Key Ingredient

• Crizotinib

Key Benefits

• Xalkori targets ALK and ROS1 gene mutations, which are responsible for cancer cell growth in certain types of lung cancer, leading to improved outcomes.
• By inhibiting abnormal proteins, Xalkori can slow or halt the progression of cancer, helping to extend survival and improve quality of life.
• Xalkori is taken in capsule form, offering ease of use compared to intravenous chemotherapy treatments.
• Xalkori is a proven, approved treatment option for cancers with these genetic mutations.

Direction of Use

• The typical starting dose for Xalkori is 250 mg taken orally twice daily. The dose may be adjusted based on the patient's response and tolerability.
• Take Xalkori with food, preferably at the same time each day to maintain a consistent level of the medication in the body.
• If you forget a dose, take it as soon as possible, unless it's almost time for your next dose. Do not take more than the prescribed amount to make up for the missed dose. 
• Regular monitoring of liver function and other potential side effects is recommended during treatment.

Safety Concerns

• Xalkori can cause liver damage, which may manifest as elevated liver enzymes or jaundice. Liver function tests should be conducted regularly.
• Xalkori may cause changes in heart rhythm (QT prolongation), so patients with heart problems or those on medications that also affect the heart should be monitored.
• Some patients may experience vision problems, such as blurred vision, light sensitivity, or seeing halos.
• Nausea, vomiting, and diarrhea are common side effects of Xalkori.
• Fatigue or weakness may occur during treatment with Xalkori.
• A rare but serious side effect is pneumonitis, which is inflammation of the lungs. Symptoms may include difficulty breathing, coughing, and fever. 

Avoid Xalkori (Crizotinib) If

• If you are allergic to crizotinib or any of the ingredients in Xalkori, avoid taking this medication.
• Xalkori should not be used in patients with severe liver impairment or significant liver disease, as it may worsen liver function.
• Xalkori should not be taken with medications that are strong inducers of CYP3A4, as they may decrease the effectiveness of crizotinib. It may also interact with medications that affect heart rhythm or liver function.
• Xalkori is classified as a pregnancy category D medication, meaning it can cause harm to a fetus. This medication should be avoided if you are pregnant or breastfeeding. 
• Patients with a history of QT interval prolongation or serious heart problems should avoid Xalkori unless carefully monitored.